SFTCG awarded two presenters at the SETGYC Biennial Congress 2022.
ESGCT would like to express our sadness
and dismay at the loss of Dr. Manfred Schmidt.
Congratulations to this year's award winning oral and poster presenters.
Un message du président de la SFTCG
Review written by Alessandro Aiuti, Giuliana Ferrari & Adrien Thrasher
New Horizons in the Management of ADA-SCID is a free educational resource for healthcare professionals managing patients with this rare disease.
To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines. The academic sector plays an important role in the development of innovative medicines. Their scientific research is often at the source of novel methodologies and innovative medicines with a potential to benefit patients with rare diseases.
Copyright ©2022 Société Française de Thérapie Cellulaire et Génique | Website by OFEC